# Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer

> **NCT06776757** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)
- **DRUG:** Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)

## Key facts

- **NCT ID:** NCT06776757
- **Lead sponsor:** Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-25
- **Primary completion:** 2025-06-25
- **Final completion:** 2025-12-25
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06776757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06776757, "Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06776757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*